A5069187235- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Diverticular Disease and Complications
- Gastric Cancer Management and Outcomes
- Primary Care and Health Outcomes
- Palliative Care and End-of-Life Issues
- Health Systems, Economic Evaluations, Quality of Life
- Esophageal and GI Pathology
- Global Cancer Incidence and Screening
- Childhood Cancer Survivors' Quality of Life
- RNA modifications and cancer
- Cardiac, Anesthesia and Surgical Outcomes
- Art Therapy and Mental Health
- Statistical Methods in Clinical Trials
- Colorectal Cancer Surgical Treatments
- Healthcare Systems and Technology
- Traumatic Brain Injury Research
- Cancer Cells and Metastasis
- Dementia and Cognitive Impairment Research
Princess Margaret Cancer Centre
2006-2024
University Health Network
2007-2024
NeoGenomics (United States)
2024
Toronto East General Hospital
2024
St Joseph's Health Centre
2024
Health Net
2023-2024
Toronto General Hospital
2013-2023
University of Toronto
2007-2013
Juravinski Cancer Centre
2006
Importance Liquid biopsy has emerged as a complement to tumor tissue profiling for advanced non–small cell lung cancer (NSCLC). The optimal way integrate liquid into the diagnostic algorithm patients with newly diagnosed NSCLC remains unclear. Objective To evaluate use of circulating DNA (ctDNA) genotyping before diagnosis among suspected and its association time treatment. Design, Setting, Participants This single-group nonrandomized clinical trial was conducted 150 at Princess Margaret...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have proven efficacy in advanced non-small-cell lung cancer (NSCLC). Their role early-stage NSCLC has not been established. Our purpose was to explore the use of preoperative gefitinib clinical stage I assess tumor response, toxicity, and molecular predictors response.Patients received 250 mg/d for up 28 days, followed by mediastinoscopy surgical resection an open-label, single-arm study. Tumor response evaluated...
Molecular profiling of tumor tissue is the gold standard for treatment decision-making in advanced non-small cell lung cancer (NSCLC). Results may be delayed or unavailable due to insufficient tissue, prolonged wait times biopsy, pathology assessment and testing. We piloted use plasma testing initial diagnostic workup patients with suspected cancer.Patients ⩽15 pack-year smoking history referred rapid program underwent circulating-tumor DNA using a DNA-based mutation panel. Tissue was...
// Adrian G. Sacher 1, 5 , Lisa W. Le 2 Humberto Lara-Guerra 3 Thomas K. Waddell Shingo Sakashita 4 Zhuo Chen 1 Lucia Kim Tong Zhang Suzanne Kamel-Reid Alexandra Salvarrey Gail Darling Kazuhiro Yasufuku Shaf Keshavjee Marc de Perrot Frances A. Shepherd Geoffrey Liu Ming Sound Tsao Natasha B. Leighl Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada Department Biostatistics, Thoracic Surgery, Pathology and Laboratory Medicine,...
Introduction: Improving health-related quality of life (hrqol) is a key goal systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact real-time electronic hrqol tool, Lung Cancer Symptom Scale (elcss-ql), on palliative care (pc) referral rates, patterns chemotherapy treatment, and use other supportive interventions patients with non-small-cell cancer (nsclc) receiving first-line chemotherapy. Methods: Patients nsclc starting were...
Objectives Diagnostic assessment programmes (DAPs) can reduce wait times for cancer diagnosis, but optimal DAP design is unknown. This study explored how organisational characteristics influenced multidisciplinary teamwork and diagnostic service delivery in lung DAPs. Design A mixed-methods approach integrated data from descriptive qualitative interviews medical record abstraction at 4 Findings were analysed with the Integrated Team Effectiveness Model. Setting DAPs 2 teaching community...
3546 Background: Given the challenges of molecular profiling in patients with advanced lung cancer, this prospective study examines clinical outcomes and utility liquid biopsy treatment naive stage IV adenocarcinoma (Cohort 1) setting resistance to targeted therapy 2; not reported here). Methods: This is being conducted at 6 Canadian centres (NCT03576937) using Guardant 360 (G360), a validated cell-free DNA next-generation sequencing assay that identifies variants 74 cancer-associated genes,...
7155 Background: NCIC CTG JBR.10 is among the landmark trials to establish 3rd generation platinum-based adjuvant chemotherapy as standard of care after complete resection stages IB-II NSCLC, improving 5-year survival by 15% and median 21 months (p 0.04). The cost-effectiveness from perspective Canada’s public health system was undertaken in a retrospective analysis based on study population. Methods: Direct medical resource utilization data, prospective trial data patients enrolled onto...
7516 Background: Erlotinib has demonstrated major activity in EGFR mutation positive NSCLC, but may also benefit those with wild-type tumours. We conducted a single-arm trial of pre-operative erlotinib early stage NSCLC to assess radiologic and functional response as well correlation known investigational biomarkers. Methods: Patients clinical IA-IIB received 150 mg daily for 4 weeks followed by surgical resection. Tumor was assessed using pre- post-treatment CT PET imaging. Pharmacodynamic...
Abstract Introduction: Patients with early-stage lung cancers have a high risk of relapse and death even after curative surgery. Detection circulating tumour DNA (ctDNA) in plasma perioperatively is associated shorter recurrence free survival (RFS). ctDNA-Lung-Detect an investigator-initiated prospective study ctDNA detection association RFS patients early stage non-small cell cancer (NSCLC). Methods: clinically staged T<4cm N0 NSCLC planned for surgical resection at the Princess...
3039 Background: Molecular profiling of tumor tissue is the gold standard for treatment decision making in advanced non-small cell lung cancer. Results may be delayed or unavailable due to insufficient samples prolonged wait times biopsy, pathology assessment and testing. We piloted use plasma molecular testing as part initial diagnostic work-up patients with suspected cancer (NCT04863924). Methods: Patients radiologic evidence referred rapid program underwent circulating DNA (ctDNA) using...